Adalimumab and Methotrexate Interaction

Drug interaction information between Adalimumab and Methotrexate.

Adalimumab and Methotrexate have a documented minor interaction in FDA labeling.

FDA drug labeling documents a minor-severity interaction between Adalimumab and Methotrexate. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Adalimumab

TNF-Alpha Inhibitor (Biologic)

Drug B

Methotrexate

Disease-Modifying Antirheumatic Drug (DMARD)

How They Interact

These two drugs are often used together to treat joint pain, and methotrexate can help the body accept the other medicine better.

FDA Label Information

( 5.10 , 7.3 ) 7.1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX).

Methotrexate Also Interacts With

View all Methotrexate interactions →

Frequently Asked Questions

What SPL severity band is on file for Adalimumab + Methotrexate?

Compiled FDA labeling labels this pair minor. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Methotrexate has 38 labeled pairs on file vs Adalimumab's 5. In the minor band specifically: Adalimumab has 4 (also Warfarin, Cyclosporine, Theophylline); Methotrexate has 26 (also Aspirin, Folic Acid, Probenecid, Phenytoin).

What mechanism field is on file for Adalimumab and Methotrexate?

These two drugs are often used together to treat joint pain, and methotrexate can help the body accept the other medicine better.

Methotrexate's labeled portfolio outnumbers Adalimumab

SPL source-record counts only. This page's band is minor · classes on file: Adalimumab (TNF-Alpha Inhibitor (Biologic)); Methotrexate (Disease-Modifying Antirheumatic Drug (DMARD)).

Adalimumab

0 major · 1 moderate · 4 minor · 5 total

Methotrexate

0 major · 12 moderate · 26 minor · 38 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.